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Abstract The study objective was to ascertain outcomes
with the Swedish adjustable gastric band (SAGB) on an
intention-to-treat basis in multiple centers across the French
social health insurance system. SAGB results at 3-year
follow-up are reported. The noncomparative, observational,
prospective, consecutive cohort study design sought a 500-
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patient minimum recruitment geographically representative
of continental France. Safety (adverse events [AEs], device-
related morbidity, and mortality) and effectiveness (change
in body mass index [BMI, kilograms per square meter], per-
centage excess weight loss, comorbidities, quality of life
[QoL]) were assessed. Adjustable gastric band survival was
calculated. Thirty-one surgeons in 28 multidisciplinary teams/
sites enrolled patients between September 2, 2007 and April
30, 2008. SAGB was successfully implanted in 517 patients:
88.0 % female; mean age, 37.5 years; obesity duration,
15.3 years (baseline: mean BMI, 41.0; comorbidities, 773 in
74.3 % of patients; Bariatric Analysis and Reporting Outcome
System (BAROS), 1.4; EuroQoL 5-Dimensions (EQ-5D),
0.61; EuroQoL–visual analog scale (EQ–VAS), 52.3). At
3 years: BMI, 32.2 (mean change, −9.0; p<0.0001); excess
weight loss, 47.4 %; comorbidities, 161 in 27.2 %; BAROS,
3.6 (+2.2, p<0.0001); EQ-5D, 0.84 (+0.22, p<0.0001); EQ–
VAS, 73.4 (+21.4, p<0.0001). SAGB-induced weight loss
was associated with substantially improved QoL. One death
occurred and was unrelated to the treatment. No AE was
reported in 68.3 % of patients, and no confirmed device-
related AE in 77.0 %. Overall AE rate was 0.19 per patient
year. Device retention was 87.0 %. Analysis of patients lost to
follow-up showed a nonsignificant effect on overall study
results. In a prospective, consecutive cohort, “real-world”,
nationwide study, the Swedish Adjustable Gastric Band was
found safe and effective at 3-year follow-up.
Keywords Laparoscopic adjustable gastric banding .
Obesity . National outcomes . Swedish adjustable gastric
band . SAGB . Quality of life . BAROS . EQ-5D . QALY
Introduction
Long-term effectiveness and safety of adjustable gastric band-
ing (AGB) is of ongoing importance to patients, surgeons, and
insurers. The most recent global survey of bariatric surgery,
incorporating 36 respondent nations/national groupings, found
that AGB utilization is in its ascendancy in the USA and
Canada, having increased in this grouping 944.2 % between
2003 and 2008 (from 9,270 to 96,800 procedures annually).
Even in Europe, where AGB use dropped 20.5 % relative to
other bariatric procedures, the number of AGB operations
per annum increased 34.2 % from 21,496 to 28,843 in the
same time frame [1]. Selection of AGB as a bariatric
treatment remains high and with several hundred thousand
patients currently in long-term follow-up, intermediate and
long-term national AGB outcome data are needed for in-
surance valuations and also as benchmarks for bariatric
surgery outcome improvement.
Between 2003 and 2008, France performed the third great-
est number of bariatric procedures annually (n013,722) after
the USA and Brazil [1]. As estimated in 2007, the majority of
bariatric procedures performed in France, 87.3 %, were AGBs
[2]. As part of its responsibility to the social insurance system
[3, 4], the French government commissioned safety and effi-
cacy studies to obtain insurance data with which to evaluate
the service to patients provided by the proprietary AGBs used
in France (e.g., Swedish Adjustable Gastric Band™
[SAGB™]). The objective of the current study, requested by
the Commission d’Evaluation des Produits et Prestations (a
branch of the French Health Technology Assessment Body,
Haute Autorité de Santé [HAS]) [5, 6] and sponsored by the
manufacturer of the SAGB, Ethicon Endo-Surgery Europe,
GmbH, was to prospectively ascertain outcomes typical of the
French experience with the SAGB. The study protocol re-
quired recruitment of at least 500 consecutive SAGB patients
(with <20 % attrition) by a representative sample of SAGB-
implanting surgeons (i.e., both very experienced and less
experienced) in urban and rural centers across regions of
continental France [7]. We present SAGB cohort outcomes
collected in 30 surgical sites between September 2, 2007 and
November 20, 2011 analyzed on an intent-to-treat (ITT) basis
with 3-year follow-up.
Methods
Study Protocol and Conduct
In 2007, at the request of the French HAS [5, 6], with the
objective of data acquisition to assess reimbursement of the
SAGB product in France, Ethicon Endo-Surgery Europe,
GmbH undertook sponsorship of a nationwide study of
SAGB outcomes in participating centers (registered in the
Clinical Trials Web database, #NCT01183975 [7]). The
sponsor developed the protocol and case report form to
implement HAS requirements and good clinical practices
(GCPs) defined in ISO EN 14155-1 and 2 [8, 9], with
consideration for real-life study constraints. The protocol
was approved by HAS, the Comité Consultatif sur le Traite-
ment de l’Information en matière de Recherche dans le
domaine de la Santé, and the Commission Nationale de
l’Informatique et des Libertés (CNIL) to ensure patient
welfare in the study methodology and the ethical conduct
of the study. The study was monitored by Contract Research
Organization, Medextens SARL, Paris, France.
All patients provided written informed consent prior to
surgery in accord with GCP guidelines and the Declaration
of Helsinki [10]. Treatment payments for patients were
covered by French National Health Insurance [6]. An inde-
pendent study-monitoring committee consisting of a medi-
cal nutritionist, a nonparticipating bariatric surgeon, and a
pharmacologist audited study conduct and the interim
report.
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Design, Setting, Recruitment
The study was of a prospective, multicenter, noncompara-
tive observational design, with consecutive recruitment of
SAGB patients by participating surgeons. Study objectives
specified by HAS were the evaluation of (1) safety by
occurrence of adverse events, (2) clinical effectiveness by
weight reduction, and (3) comorbidity and quality of life
(QoL) improvement. Beyond the protocol prescribing stan-
dardized safety and weight data collection and assessment,
no other standardization of physical examinations, laborato-
ry work, radiology studies, or follow-up procedure(s) (e.g.,
band adjustments) was feasible or appropriate, given the
independent, real-life assessment of participating centers.
The study was designed to record safety and effective-
ness in morbidly obese patients who underwent SAGB
implantation in French hospitals. Patients were eligible for
surgery when presenting with a body mass index (BMI,
kilograms per square meter) ≥40 or ≥35 to <40 with comor-
bidities after failure of medical treatment in the absence of
contraindications in accord with published guidelines [11,
12]. Patients in whom SAGB implementation was a bariatric
re-intervention were also part of consecutive enrollment. A
minimum recruitment goal of 500 patients with <20 % loss
to follow-up at 3 years was targeted.
Inclusion Criteria
Surgeons were selected in public, academic, and private
institutions geographically distributed across continental
France that had varying degrees of bariatric surgery volume.
The goal was to include surgeons and patients who would
provide SAGB outcomes representative of the broad French
real-life practice. In compliance with GCP standards, all
surgeons underwent training in the study protocol.
All patients consecutively undergoing SAGB implantation
during the recruitment period by participating investigators
were included in the cohort, providing that they resided in
continental France and had signed informed consent. Accord-
ing to routine practice requirements, these patients were
expected to meet French guidelines for bariatric surgery [5]
(similar to National Institutes of Health [11] and the European
Guidelines on Surgery of Severe Obesity [12]), and to be
eligible based on the HAS criteria [5, 6].
Variables
Primary safety variables were frequency of adverse events,
mortality, and medical device-related morbidity. The prima-
ry effectiveness variable was ITT BMI change over the
course of 3 years. Secondary effectiveness variables were
absolute weight, excess weight, percentage excess weight
loss (%EWL; i.e., difference in preoperative and follow-up
weight divided by excess weight, calculated by Miller’s
formulas [13–17] for ascertaining ideal weight, which cor-
respond to the midpoint value of the medium-frame range
on the Metropolitan Life Insurance Height and Weight
Tables, multiplied by 100), health-related QoL, and propor-
tional changes in comorbidities.
QoL Instruments
The Bariatric Analysis and Reporting Outcome System
(BAROS), introduced by Oria and Moorehead in 1998
[18, 19], is a well-validated bariatric-specific QoL assess-
ment that integrates weight loss data, comorbidity changes,
and subjective QoL, complications, and reoperations. A
maximum of three points are recorded within domains of
weight loss, comorbidity improvement, and subjective QoL;
points are deducted for complications and reoperations. The
final score classifies outcomes as failure (≤1), fair (>1 to 3),
good (>3 to 5), very good (>5 to 7), or excellent (>7 to 9).
The EuroQoL 5-Dimensions (EQ-5D) was selected as the
generic complement to the BAROS due to its usefulness in
calculating quality adjusted life years (QALYs). Specifical-
ly, the EQ-5D has proven effective in the estimation of the
relative cost effectiveness associated with obesity interven-
tions, including AGB [20]. The EQ-5D is a generic health-
related QoL assessment comprised of five items and a Euro-
QoL–visual analog scale (EQ–VAS) [21–24] yielding a
patient health profile along five dimensions mobility, self-
care, usual activities, pain/discomfort, and anxiety/depres-
sion. Each dimension is represented by one item with three
response options no problem, some problems, and severe
problems. Responses to these five items can be normatively
weighted to derive an EQ-5D utility score with a range
of −0.594 to 1 (10ultimate health). A difference of ≥0.07
in EQ-5D utility has been identified as clinically important
[24]. The EQ–VAS component represents a single-item
global QoL assessment in which patients are asked to rate
their current health on a scale from 0 (worst imaginable) to
100 (best imaginable) [25].
Technique, Band Adjustment
Gastric banding was performed via standardized pars flac-
cida technique [26]. SAGB model options were 2100-X
(with locking ring and injection port); 2200-X Quick-
Close; and BD2XV Quick-Close with Velocity™ injection
port. Band adjustments were performed according to the
discretion of participating surgeons.
Data Collection
Baseline patient characteristics were collected (e.g., gender
and age); weight, obesity-related comorbid disease, and
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QoL were recorded preoperatively, and assessed at 1, 3, 6,
12, 18, 24, and 36 months postoperatively. Comorbidity
data were obtained via questionnaire with diagnoses estab-
lished according to each investigator’s usual practice.
Remote entry of clinical data was performed by inves-
tigators or administrative support personnel via password-
protected access to the Medextens-Medalliance eCRF
Manager (v.1.3) web database (CNIL registered, www.
medalliance.fr). Patients were informed of their rights of
access, correction, and refusal to participate.
Statistical Analysis
Stata/MP software (v.11.2, StataCorp LP, College Station,
TX, USA) was used to perform all statistical analyses.
Statistical command syntax was programmed as a repeatable
and auditable script. Statistical analysis was performed
according to International Conference on Harmonization
E9 guidance. No statistical justification for sample size is
presented herein, as determination of the number of consec-
utive patients required was pre-established by HAS specifi-
cations. Continuous demographic variables were reported as
mean, standard deviation (SD), and 80 % interpercentile
range. Categorical demographic variables (including preop-
erative BMI subgroups) were reported as number and per-
centage. Comorbidity data and adverse events were also
reported as number and percentage. Implant-survival rate
and associated 95 % confidence interval (CI) was calculated
using the Kaplan–Meier method. Continuous outcome var-
iables were generally reported as mean, SD, and 95 % CI. A
qualitative assessment of comorbidities before and after
SAGB implantation was carried out. Fisher’s exact test
was used to investigate relationships between categorical
variables. Between-group comparisons along continuous
measures were conducted using two-tailed, independent-
sample t tests. In addition, a series of two-tailed, single-
sample t tests were performed to assess within-patient
change from baseline, adopting a null hypothesis of no
significant mean change in weight and QoL variables
(H000, based on the nature of the disease of obesity without
intervention). The Shapiro–Wilk test for normality was con-
ducted on each variable distribution prior to t test. Linear
regression was applied in the analysis of relationships be-
tween QoL measures, as well as in the relationship between
BMI and QoL. Statistical significance was set at p≤0.05.
Results
Initially, 51 surgeons were identified as trained to implant
the SAGB based on previous year records of performing ≥1
bariatric procedure weekly and, specifically, 35 AGB pro-
cedures annually. Forty surgeons enlisted, 37 created patient
records in the database, 31 of which actively contributed to
the cohort (note: five surgeons reconsidered their ability to
effectively participate in the study and voluntarily withdrew
during the patient recruitment phase; one surgeon was ex-
cluded from the study during the data validation process due
to marked protocol noncompliance; the 63 patient records
created by the six surgeons were deemed invalid). These 31
surgeons were part of 28 multidisciplinary teams in five
university hospitals, three general hospitals, and 23 private
institutions. Patient screening and enrollment began Sep-
tember 2, 2007 and concluded April 30, 2008. The final 3-
year follow-up visit was due on April 30, 2011 but was
extended to November 20, 2011 to accommodate patient
availability.
The 31 surgeons who contributed to the cohort performed
a total of 1,239 bariatric procedures during the study period,
of which 560 cases were recorded in the online database as
consecutive SAGB patient records. Among the 560 records,
43 were deemed invalid because they contained data entry
errors, were duplicates, SAGB implantation was not docu-
mented, or because patients withdrew. Overall, 517 valid
consecutive patients records were included in the database
analysis. Participating surgeons performed an average of
16.7 SAGB implants. The majority of cases (514/517,
99.4 %) were performed laparoscopically; conversions to
laparotomy were reported in two cases (0.39 %); 99.6 %
(515/517) used pars flaccida technique; 76.4 % (395/517)
employed band fixation; and 49.13 % (254/517) used port
fixation. Immediate band filling occurred in just 0.58 % (3/
517) of cases. Overall, 66.54 % (344/517) of SAGB
implants were performed using model 2200X; model
BD2XV was used in 33.27 % (172/517) of cases.
Safety and weight data met completeness and accuracy
criteria required by the protocol. Three-year clinical out-
come data were available in 85.9 % (444/517) of the cohort;
the objective that <20 % of patients lost to follow-up at
3 years was reached. Due to the observational nature of this
study with significant differences between surgeons in terms
of their routine practice, comorbidity and QoL data did
not meet protocol-targeted completeness; comorbidity da-
ta was available for 78.0 % of the SAGB cohort at 3-year
follow-up, while QoL data availability at 3 years ranged
from 39.0 % to 78.0 %, depending on the complexity of
the instrument.
Baseline Patient Characteristics
In the 517 consecutive patients with confirmed SAGB implants,
gender and age were reported in 516 patients (99.8 %); disease
duration in 504 patients (97.5 %); height, weight, excess
weight, and BMI in 513 patients (99.2 %). The cohort consisted
of 88.0 % (n0455) female and 11.8 % (n061) male, with a
mean age of 37.5±10.9 years, obesity duration of 15.3±
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8.4 years, BMI of 41.0±4.9 kg/m2, absolute weight of 111.4±
16.8 kg, and excess body weight of 52.1±14.1 (Table 1).
AGB was the first bariatric surgery in 471 patients
(91.1 %) and a re-intervention in 43 patients (8.3 %). There
were 291 patients (56.3 %) with a BMI of ≥40; 193 (37.3 %)
with a BMI of ≥35 to <40; 29 patients (5.6 %) presented with
a BMI of <35. Baseline BMI could not be calculated in four
patients (0.77 %) due to missing weight and/or height data.
Patients with ≥1 comorbidity numbered 384 (74.3 %),
with a total of 781 recorded comorbidities. A history of
family obesity was reported in 343 patients (66.3 %) and
475 patients (91.9 %) had ≥1 year of specialized medical
care prior to SAGB. Mean BAROS was 1.4±1.4, mean EQ-
5D was 0.61±0.31, and mean VAS was 52.3±18.4.
Adverse Events
The majority of SAGB patients (68.3 %, 353/517) experi-
enced no adverse events (AEs) of any kind. Also, no con-
firmed device-related AE or serious adverse events (SAEs;
life-threatening or disabling event requiring intervention) was
reported in 77.0 % (398/517). Confirmed AEs and/or SAEs
associated with the SAGB procedure totaled 290 in 164
patients (31.7 %) intraoperatively and up to 3-year follow-
up. There were 153 (29.6 %) AEs and 137 (26.5 %) SAEs
constituting an overall rate of 0.19 adverse event per patient
year. There was one death caused by an accident unrelated to
the procedure. Figure 1 shows the distribution of the 290
confirmed events with a peak event frequency of 42 events
during the first quarter following SAGB implant; thereafter,
frequency was approximately 10 events per quarter.
Among 290 confirmed events, there were 143 device-
related events in 119 patients (23.0 %); thus, the device-
related event rate was 0.09 event per patient year. The most
frequent device-related AEs were 22 (4.3 %) band slippages,
14 (2.7 %) esophageal dilations, 13 (2.5 %) pouch dilations,
13 (2.5 %) port malpositions, 9 (1.7 %) port rotations, and 7
(1.4 %) port disconnections, 5 (1.0 %) food intolerances, 5
(1.0 %) dysphagia, 4 (0.8 %) band infections, 3 (0.6 %) port
infections, 3 (0.6 %) band-related blockages, and 3 (0.6 %)
Table 1 Baseline characteristics
for 517 total patients receiving
SAGB implant
SD standard deviation, IPR
interpercentile range (the 80th
IPR indicates variable values
ranging from 10th to 90th per-
centile), BMI body mass index,





aN = 302 fo r BAROS da ta
recorded at 30 days postoperative
bN=449 with EQ-5D data at
inclusion




Male, N (%) 61 (11.8)
Female, N (%) 455 (88.01)
Age, mean±SD, years (80 % IPR) 37.5±10.9 (23.4 to 53.7)
Duration of obesity, mean±SD, years (80 % IPR) 15.3±8.4 (6.0 to 28.0)
Height, mean±SD, m (80 % IPR) 1.7±0.1 (1.6 to 1.8)
Absolute weight, mean±SD, kg (80 % IPR) 111.4±16.8 (93.0 to 133.0)
Excess body weight, mean±SD, kg (80 % IPR) 52.1±14.1 (37.8 to 71.0)
BMI, mean±SD, kg/m2 (80 % IPR) 41.0±4.9 (36.1 to 47.3)
BMI ≥40, kg/m2, N (%) 291 (56.3)
BMI ≥35 and<40, kg/m2, N (%) 193 (37.3)
BMI <35, kg/m2, N (%) 29 (5.6)
At least 1 comorbidity, N (%) 384 (74.3)
History of family obesity, N (%) 343 (66.3)
1-year specialized medical care and multidisciplinary assessment, N (%) 475 (91.9)
First bariatric intervention, N (%) 471 (91.1)
Preoperative psychological evaluation, N (%) 503 (97.3)
BAROSa, mean±SD (80 % IPR) 1.4±1.4 (−0.3 to 3.0)
EQ-5Db, mean±SD (80 % IPR) 0.61±0.31 (0.09 to 0.88)
EQ–VASc, mean±SD (80 % IPR) 52.3±18.4 (30.0 to 80.0)
Fig. 1 Time distribution of adverse events or re-interventions
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band-related records of frequent vomiting. Device-related
SAEs included 67 (13.0 %) band removals, 23 (4.4 %)
abdominoplasties, 22 (4.3 %) port re-interventions without
port removal, 8 (1.6 %) port removals, and 3 (0.6 %) band
re-interventions without removal.
Implant Survival Rate Function
SAGB removals occurred at different intervals post implanta-
tion. The risk of failure (SAGB removal) versus the chances of
success (SAGB retention) over time was estimated with
Kaplan–Meier cumulative survival function. All reported
removals were included in the analysis (Fig. 2). Patients with
SAGB in place at the date of database freeze (November 20,
2011) were censored. The 517 valid implanted patients were
exposed to a time-at-risk of 23,386 months. Sixty-seven fail-
ures were confirmed; band removal was typically associated
with the most severe adverse events. Median time at risk was
48months and the last recorded failure date was 50.23 months
following implantation. At 3 years, SAGB implant survival
rate was 87.0 % (95 % CI: 83.7, 89.6).
Weight Loss
Three-year postoperative outcomes were available in 85.9 %
(444/517) of patients. Intention-to-treat BMI change over
the course of 3 years was available in 423 (81.8 %) patients,
including 373 patients with SAGBs still in place and 50
patients whose bands were removed. BMI change could not
be calculated in 94 patients, including 73 lost to follow-up
with unknown outcomes, 13 with band removals, 7 with
incomplete data, and 1 death. Mean absolute weight was
87.1±17.6 kg (85.4, 88.8) compared to 111.6±16.9 kg
(110.0, 113.2) at baseline (Table 2). This represented a mean
absolute weight reduction of 24.5±14.6 kg (23.1, 25.9;
t[422]034.4, p<0.0001). Mean excess body weight was
28.0±15.8 kg (26.5, 29.5) compared to 52.5±14.3 kg
(51.1, 53.8) at baseline, a reduction in excess weight of
24.5±14.7 kg (23.1, 25.9; t[421]034.3, p<0.0001)
corresponding to a %EWL of 47.4±32.1 (44.3, 51.0). Mean
BMI was 32.2±5.8 (31.6, 32.7), down approximately
22.0 % from 41.2±5.0 (40.7, 41.7). This change in patient
BMI represented a mean reduction of 9.0±5.3 (8.5, 9.5;
t[422]035.0, p<0.0001). Figure 3 depicts the cohort’s evo-
lution in mean BMI, beginning with a maximum adult BMI
of 42.8±4.9 (42.3, 43.2).
A significant difference in preoperative mean BMI was
observed between patients receiving SAGB as a first inter-
vention and those receiving SAGB as a re-intervention
(41.4±4.4 vs 37.1±7.4, p<0.001); however, by 3-year
follow-up, mean BMI was not significantly different (32.1
±5.8 vs 32.8±5.6; p00.51) between these two groups of
patients. In order to assess the risk of bias in estimating the
Fig. 2 Kaplan–Meier band survival curve
Table 2 Three-year weight outcomes and mean change assessment
Weight variable Value P valueb
Mean±SD (95 % CI)
N0423a
Preoperative 3 Years Mean change
Absolute weight, kg 111.6±16.9 (110.0, 113.2) 87.1±17.6 (85.4, 88.8) −24.5±14.6 (−25.9, −23.1) <0.0001
Excess body weight, kg 52.5±14.3 (51.1, 53.8) 28.0±15.8 (26.5, 29.5) −24.5±14.7 (−25.9, −23.1) <0.0001
BMI, kg/m2 41.2±5.0 (40.7, 41.7) 32.2±5.8 (31.6, 32.7) −9.0±5.3 (−9.5, −8.5) <0.0001
% EWL – 47.4±32.1 (44.3, 51.0) – –
BMI body mass index, EWL excess weight loss, SD standard deviation, CI confidence interval
aN0423 for absolute weight and BMI within-patient change calculations; N0422 for excess weight within-patient change and %EWL calculations
bP values obtained from single-sample two-tailed t tests assessing mean weight change in patients with complete preoperative and 3-year follow-up
data
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primary endpoint on an ITT basis, patients with and without
3-year follow-up weight data were compared on several
variables that could potentially influence BMI change.
Mean preoperative BMI of patients with complete 3-year
weight data relative to those without were not significantly
different (41.2±5.0 vs 40.3±4.6; p00.10). Age at baseline,
gender, duration of disease, maximum adult BMI, SAGB as
first intervention or re-intervention, SAGB model type, and
frequency of band removal were also not significantly dif-
ferent between groups.
In addition, the magnitude of the effect of including patients
with band removal in the calculation of BMI change over
3 years was also assessed. As expected, a significant difference
in mean BMI changewas observed between patients with band
ablation vs patients with intact SAGBs at 3 years (−6.2±5.5
vs −9.4±5.2, p<0.001); however, the inclusion of patients with
band ablation (in conformance with ITT analysis) had a non-
significant effect on the overall cohort mean change value
(−9.0±5.3 [−9.7, −8.4] vs −9.4±5.2 [−10.1, −8.7]). Overall,
BMI reduction was observed across visits with most of the
reduction occurring during the first postoperative year, con-
tinuing through the second year, followed by a negligible BMI
increase during the third year (Fig. 3).
Comorbidities
Adhering to the study’s observational design, the protocol did
not seek to modify current diagnostic or therapeutic practices:
no protocol-driven diagnostic tests were required. At each
follow-up visit, comorbidities were generally reported as
“present” or “absent.” Significant variation in diagnostic
methodology, terminology, and reporting regularity was not-
ed. Investigators, themselves, often did not assess comorbid-
ities, but rather, reported assessment results provided to them
by third parties. As a result, it was determined that an under-
reporting bias was a distinct possibility, thus limiting the
reliability of a quantitative estimate of change in prevalence.
Arthropathy (38.0 %), hypertension (22.0 %), dyslipide-
mia (20.0 %), gastroesophageal reflux disease (20.0 %),
obstructive sleep apnea (12.0 %), and diabetes (10.0 %)
were the most frequently cited comorbidities at baseline,
each experienced by at least 10 % of the cohort. Qualitative
analysis suggested a continued reduction in the overall
number of comorbidites over time and a gradual increase
in number of patients with no reported comorbidities. Using
recorded weight as an indicator of data integrity, 773 comor-
bidties were reported at baseline in 74.3 % (381/513) of
patients with concomitant weight data, while no comorbid-
ity was reported in 25.7 % (132/513). At 3-year follow-up,
161 comorbidities were reported in 27.2 % (116/426) of
patients with concomitant weight data, while no comorbid-
ity was reported in 72.8 % (310/426). In addition, the
number of patients with multiple comorbid conditions was
reduced at 3 years and the mean number of comorbidities
per patient fell from 1.5 at baseline to 0.4 at 3-year follow-
up. Analysis also suggested a slight increase in the average
number of comorbidities per patient from year 2 (visit 7) to
year 3 (visit 8), paralleling the modest weight regain over
the same time period.
Quality of Life
Although patient QoL assessment participation did not meet
the protocol objective for data completeness, there were
sufficient data to carry out quantitative analyses. [Note:
Patient participation diminished with the complexity of the
three QoL instruments.] All measures of QoL over time
were significantly improved (Table 3). At 3 years, for
patients with complete data, mean BAROS was 3.6±2.2
(3.2, 4.0) compared to 1.4±1.3 (1.2, 1.6) at pseudo-
baseline (i.e., 30 days post SAGB). This positive change
in bariatric-specific QoL represented a mean increase of 2.2
±2.2 (1.8, 2.6; t[133]011.9; p<0.0001). Figure 4 depicts the
cohort’s upward trend in mean QoL as assessed by BAROS
over the course of the study. Mean EQ-5D utility score was
0.84±0.21 (0.82, 0.86) relative to a baseline value of 0.62±
0.31 (0.59, 0.65). This represented a mean within-patient
QoL improvement of 0.22±0.32 (0.19, 0.25; t[346]0
12.6; p<0.0001), thus, a mean utility gain of 0.66 QALY
over 3 years. Mean EQ–VAS score was 73.4±17.1 (71.6,
75.2) compared to 52.0±18.4 (50.1, 53.9), a QoL in-
crease of 21.4±22.8 (19.0, 23.7; t[353]017.7; p<0.0001).
Regression analysis indicated a significant association
between weight loss and the EQ-5D (although weight per
se is not a focus of the EQ-5D questionnaire). Using EQ-5D
individual change scores as the response variable while
controlling for baseline BMI, BMI reduction over the 3-
year period following SAGB intervention was significantly
related to an increase in global QoL (adjusted R200.03; F(2,
339)06.93; p<0.01; Fig. 5). In addition, individual change
Fig. 3 SAGB cohort body mass index evolution
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scores on the BAROS and the EQ-5D were shown to cor-
relate at r00.43, p<0.01. Overall QoL results suggest that
EQ-5D, a patient-reported QoL outcome measure with min-
imal response burden, may be a sufficient measure of QoL
following SAGB surgery.
Discussion
The current study was representative of the SAGB standard
of care in France and met the objectives defined in the
protocol in line with CEPP requirements. Results were
supportive of the clinical safety and effectiveness of the
SAGB, as concluded in prior studies. Clinical outcomes
were available for 86 % of the SAGB cohort; analysis
indicated that patient data lost to follow-up over 3 years
had no significant effect on treatment outcomes.
No treatment-related mortality was reported. AGB oper-
ative mortality is typically <0.1 % [27, 28] and 30-day to 2-
year mortality, 0.07 % [29]. Risk related to this treatment
consisted of adverse events or SAEs requiring intervention
in 31.7 % of patients, including device-related events re-
quiring intervention in 23.0 %. Band removal occurred in
just 13.0 % of patients and was usually associated with the
most severe adverse events or lack of procedure effective-
ness. At 3-year follow-up, device retention was 87.0 %.
Analysis suggested a reduction in overall comorbidites and
an increase in the number of patients with no reported
comorbidity.
A significant and sustained BMI reduction of 9.0 was
observed, corresponding to 47.4 % EWL. BMI reduction
was significantly associated with an increase in patient QoL,
as has been shown in other AGB studies [30]; the BAROS
scale showed a significant 2.2-point improvement from 30-
day visit to 3-year follow-up. On average, SAGB patients
tended to move from a BAROS QoL rating of “fair” to
“good.” Also, SAGB patient EQ-5D Qol-related utility
score significantly improved by 0.22 points (three times
the reported minimally important difference) representing a
utility gain of 0.66 QALY. In addition, the SAGB cohort’s
Table 3 Three-year quality of life outcomes and mean change assessment
QoL variable Value P valueb
Mean±SD (95 % CI)
Baseline 3 Years Mean change
BAROS 1.4±1.3a (1.2, 1.6) 3.6±2.2 (3.2, 4.0) 2.2±2.2 (1.8, 2.6) <0.0001
EQ-5D 0.62±0.31 (0.59, 0.65) 0.84±0.21 (0.82, 0.86) 0.22±0.32 (0.19, 0.25) <0.0001
EQ–VAS 52.0±18.4 (50.1, 53.9) 73.4±17.1 (71.6, 75.2) 21.4±22.8 (19.0, 23.7) <0.0001
BAROS Bariatric Analysis and Reporting Outcome System, EQ-5D EuroQoL 5-Dimensions, EQ–VAS EuroQoL–visual analog scale, SD standard
deviation, CI confidence interval
a BAROS data at 30 days postoperative functions as pseudo-baseline
bP values obtained from single-sample two-tailed t tests assessing mean QoL change in patients with complete preoperative and 3-year follow-up
data (i.e., N0134 for BAROS, N0347 for EQ-5D, N0354 for EQ–VAS)
Fig. 4 Evolution of SAGB cohort quality of life scores as measured by
the Bariatric Analysis and Reporting Outcome System (BAROS®)
Fig. 5 Relationship between body mass index reduction and quality of
life changes as measured by EuroQoL 5-dimensions (EQ-5D). v10
baseline; v803-year follow-up
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EQ-5D mean utility score of 0.84±0.21 at 3 years was
slightly higher than that recorded for a UK general practice
reference group of normal BMI patients (n0782), EQ-5D0
0.80±0.22 [31]. Overall, patient QoL change scores on
BAROS and EQ-5D were shown to be significantly corre-
lated (r00.43, p<0.01) and both instruments were sensitive
to BMI reduction over time. Results suggested that the EQ-
5D, a self-report generic QoL measure with minimal re-
sponse burden, may be a sufficient measure of QoL change
following SAGB surgery. Finally, at 3-year follow-up, trend
analysis indicated a modest and nonsignificant weight in-
crease (p00.14) beginning after year 2. Also, a corresponding
decrease in QoL and a related increase in the average number
of comorbidities suggested that SAGB patients may require
more support after year 2.
As of April 25, 2012, more than 2,300 peer-reviewed
articles addressed the topic of AGB treatment [32]. The
preponderance of these studies are of an observational de-
sign, in addition to several dozen randomized controlled
trials (RCTs), most conducted in bariatric surgery “centers
of excellence” (COEs)—experienced, high-volume medical
centers that incorporate a multidisciplinary team approach
[33] and compulsory pre- and post-operative protocols con-
forming to professional [34–36] and national [5, 11, 12]
guidelines. Outcomes achieved in COE-standard sites may
not be comparable to those achieved in less-experienced,
lower-volume sites. Yet, non-COE sites represent a sizeable
number of centers performing bariatric surgery, a fact im-
portant to insurers assessing the value of AGB treatment on
a national scale. Thus, while seven high-volume single-
center AGB studies over the last 10 years reported
≥55.0 % EWL at ≥3 years [37–43], integrated COE- and
non-COE nationwide %EWL results are somewhat lower
[44, 45].
The current study’s findings should be discussed in the
context of evidence from other national AGB studies with
intermediate-term follow-up, yet such reports are few. In the
last decade, fewer than three dozen national bariatric surgery
studies (16 large sample, retrospective, database analyses
[46–61], 14 prospective surveys [1, 2, 62–73], and one
ongoing [multi-article], nonrandomized, prospective con-
trolled study [74]) have been published in the peer-
reviewed literature, 14 of these featuring European
countries. In the seven nationwide studies with ≥2-year
follow-up data in morbidly obese patients (five observation-
al AGB or AGB-inclusive studies and two French AGB
surveys [2, 26, 58, 71, 74–76]), weight loss was less than
or comparable to that of the current SAGB cohort.
In 2003, Angrisani et al. published the Italian Lap-Band
experience with 1,863 patients in 27 centers, one of
the earliest and largest nationwide AGB studies with
intermediate-term follow-up based on a retrospectively an-
alyzed national database, the Italian Group for Lap-Band
(GILB) [58]. At baseline, patients had a mean BMI of 43.7
and 34.1 at 3 years post-AGB treatment, a reduction of 9.6
with >70 % follow-up (%EWL was not reported). These
results are similar to those of the current French SAGB
cohort where baseline BMI was 41.0, and 32.2 at 3 years,
a reduction of 9.0 (p<0.0001) with 81.8 % follow-up. In
2012, a subsequent nationwide AGB study of the same
GILB database, a comparison of the perigastric (PG) and
pars flaccida (PF) techniques was undertaken by Di Lorenzo
et al. [26] in 2,549 Lap-Band patients (baseline BMI, 46.4):
1,206 (47.3 %) were operated via PG, 1,343 (52.7 %) via
PF, approach. In patients eligible for minimum 3-year
follow-up, respective mean BMI was 33.8 (a reduction of
12.6) and 32.4 (−14.0), and mean EWL was 47.2 % and
48.9 %. These results, as in the earlier GILB cohort [58] are
essentially equivalent to those of the current study.
The third nationwide AGB report, by Phillips et al., a
prospective US Food and Drug Administration trial of the
SAGB (the “Realize® Band” in the USA) was conducted in
12 academic and private centers with surgeons versed in
laparoscopic surgery but with varied AGB experience [75].
Of 405 patients screened, 276 qualified for the study and
underwent band surgery. Mean baseline BMI was 44.5 with
a reduction of 8.2 at 3 years and 83.0 % follow-up; EWL in
the REALIZE trial was 41.1 % compared to 47.4 % in the
current French SAGB cohort.
Two nationwide AGB-related government-commissioned
surveys have been conducted in France. Chevallier et al. [71]
published a prospective, consecutive series, statistical analysis
of factors predictive of AGB outcomes from a national public
insurance perspective. Although this survey lacked 3-year
data, it found that EWL was <50.0 % at 1–2 years in the
majority of 1,079 morbidly obese adults who had undergone
the AGB procedure [71]. Basdevant et al. [2] studied current
bariatric surgery practices across procedures in the same
French National Medical Insurance Service registry as that
studied by Chevallier et al. They showed a BMI reduction of
9.9 and EWL of 46.0 % at 2 years, roughly equivalent to the
French SAGB cohort 3-year outcomes. The single prior
French clinical trial of an AGB with 3-year follow-up, a study
of the MIDBand (MID, Dardilly, France), was conducted in
13 centers (two academic, one public general hospital, 10
private clinics) in 262 morbidly obese adults, 193 of whom
were included in the weight-loss analysis (26 % lost to follow-
up). Mean baseline BMI was 41.8 with a reduction of 8.2–
30.7 at 3 years; median EWL was 61.0 % [76]. Percentage
EWL ranges reported at 2–3 years in the three prior French
AGB studies, taken together with the French SAGB cohort
study, are likely representative of current AGB weight loss
outcomes in France.
Chevallier et al. also found that, independent of patient
characteristics, the key predictor of AGB success was surgical
volume (i.e., multidisciplinary team typically performing >2
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bariatric procedures per week) [71]. Interestingly, although the
current French SAGB study incorporated centers that per-
formed <2 bariatric procedures per week, its mean %EWL
exceeded or equaled that of five of the six other national AGB
studies summarized.
A final prominent, long-running, nationwide clinical tri-
al, the Swedish Obese Subjects (SOS) study, also reported
BMI reduction less than that of the current 3-year French
study, although it is typical for weight loss to diminish
somewhat after reaching its peak between 1 and 3 years.
The SOS study is an ongoing, nonrandomized, prospective,
controlled study that has followed 480 primary healthcare
sites and 25 public surgical departments in Sweden since the
recruitment phase (September 1, 1987 to January 31, 2001).
Bariatric surgery (gastric bypass, vertical banded gastro-
plasty, or AGB [n0156 at baseline]) was performed on
2,010 morbidly obese patients and 2,037 contemporaneous-
ly matched morbidly obese controls received usual care in
the Swedish primary care system. In 2004 (10-year follow-
up), the reported mean BMI in the AGB subgroup (n0156)
had decreased by 5.4 (12.8 %, p<0.05) to 36.5 from 41.9±
4.2 (total surgical group—AGB alone, not reported) at base-
line [74].
In addition to the small number of nationwide AGB
studies with ≥3 years of follow-up, the current outcomes
should be compared with those of systematic reviews or
meta-analyses, which typically include a wide sample of
studies, possibly limiting bias toward COE “center effects.”
In considering AGB studies prior to 2003, a systematic
review by Chapman et al. concluded that the quality of
AGB studies with intermediate follow-up (defined as 2–
4 years) was only moderate, and long-term effectiveness
(>4 years), unproven [77]. Five years later, a systematic
review by Tice et al. (sponsored by US insurer Blue Shield
of California comparing 1966–2007 AGB and Roux-en-Y
gastric bypass outcomes) found similarly that, despite being
a popular procedure, AGB results beyond a single postopera-
tive year were seldom reported [78]. Four other systematic
reviews and/or meta-analyses published in the last decade
reviewed %EWL and/or BMI change at ≥1 year, though these
echo conclusions by Chapman et al. and Tice et al. that ≥3-
year AGB outcomes were few, and limited in most studies, by
marked patient loss to follow-up [44, 45, 79, 80].
In a 2004 meta-analysis by Buchwald et al. that included
1,848 patients with AGB %EWL data (1995–2003), EWL
of 47.5 % at >2 years was nearly identical to that of the
current French SAGB study EWL, 47.4 % at 3 years [44]. A
2006 systematic review by O’Brien found 54.8 % weighted
mean EWL at 3-year follow-up (AGB n03,104, 12 studies)
[79]; a 2008 meta-analysis by Cunneen et al. comparing
SAGB (n04,274, 33 studies) and Lap-Band (n024,707,
104 studies) found respective 3-year EWL of 56.4 % and
50.2 % [80]; and a 2009 meta-analysis by Garb et al.
comparing AGB and gastric bypass found 55.2 % EWL in
the AGB group (n07,383, 18 studies) at 3 years [45]. While
3-year mean %EWL in the recent three reviews was greater
than that of the current nationwide study, as would be
expected with a greater proportion of higher-volume sites
and inclusive of RCTs, the mean %EWL 95 % confidence
interval (95 % CI: 44.0, 51.0) of the current study was found
to overlap with 95 % CIs reported in the two most recent
and largest meta-analyses, suggestive of relatively compa-
rable outcomes.
Most intermediate-term AGB studies demonstrate high
rates of patient attrition, up to 86.2 % at >3-year follow-up
[45], and incomplete data collection. Although the current
study satisfied the <20 % loss to follow-up with respect to
weight and safety data, it was somewhat limited by issues
related to incomplete and missing data, particularly in the
areas of comorbidity and QoL data collection. Indeed, due
to a likely underreporting bias, a reliable quantitative esti-
mate of change in prevalence of any specific comorbidity
could not be calculated. Missing QoL data was evident even
at baseline, ranging from 13.0 to 42.0 %, again, depending
on the complexity of the instrument. In addition, although
91.1 % of patients in this cohort satisfied eligibility criteria,
in some cases, eligibility requirements were varied accord-
ing to individual investigator discretion: Under the protocol
requirement of consecutive recruitment, 29 patients (5.6 %)
presented with a BMI <35 who either had a severe concom-
itant comorbidity or maximum adult BMI of ≥45 and were
implanted with a SAGB as a re-intervention for a failed or
previously complicated bariatric procedure. In the subset
analysis of re-intervention patients, it was shown that the
inclusion of these patients in the overall cohort calculations
had a nonsignificant effect on mean BMI change; indeed, no
significant difference in mean BMI was observed at 3-year
follow-up between re-intervention patients and SAGB first-
intervention patients (32.81±5.6 vs 32.13±5.8, p00.51).
As longer-term AGB data accumulate and bariatric sur-
geons and insurers seek to analyze the “big picture” of
bariatric surgery, specifically, the clinical effectiveness of
the AGB procedure, the opportunity to review published
findings from the full range of sites performing bariatric
surgery will be important. This report presents the first
government-commissioned clinical trial results for the
Swedish Adjustable Gastric Band in routine use in multiple
centers across France.
SAGB treatment was safe and effective. At 3-year
follow-up, 87.0 % of SAGB implants were fully functional
and a significant BMI reduction of 9.0 kg/m2 with a
corresponding 47.4 % EWL was observed. The cohort’s
EQ-5D QoL-related utility score improved significantly
and was found to be essentially equivalent to that of patients
with normal BMI. These findings corroborate prior French
countrywide AGB insurance surveys and compare favorably
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with other national AGB outcome studies, systematic reviews,
and meta-analyses. More long-term nationwide studies of
AGB outcomes are needed to further clarify reimbursement
criteria and refine treatment standards.
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